ASX-listed Kiwi biotechnology company Volpara Health Technologies has recommended shareholders accept an offer to acquire all its shares, in a deal that values the company at close to A$300 million.
The Wellington-based company, which has a core mission for the early detection of breast cancer, said
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
